Repligen (NASDAQ:RGEN) Stock Price Down 6.3% - Here's Why

Key Points

• Repligen shares fell 6.3% to about $169.66, with trading volume down 55% from its average.
• Analyst sentiment remains positive, with a consensus “Buy” rating and an average price target of $166.43, although the target is below the current share price.
• The company exceeded quarterly expectations, reporting $0.54 in earnings per share versus $0.45 expected and $204.13 million in revenue, up 11.9% year over year. However, its valuation remains elevated, with a P/E ratio above 230.

Shares of Repligen Corporation (NASDAQ:RGEN - Get Free Report) fell 6.3% on Tuesday . The company traded as low as $169.41 and last traded at $169.6550. 460,096 shares changed hands during trading, a decline of 55% from the average daily volume of 1,014,037 shares. The stock had previously closed at $180.98.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on RGEN. Citigroup raised shares of Repligen to a "buy" rating in a report on Tuesday, July 7th. Evercore reaffirmed an "outperform" rating and set a $160.00 price objective on shares of Repligen in a research note on Monday, July 6th. Jefferies Financial Group reaffirmed a "hold" rating and set a $142.00 target price on shares of Repligen in a report on Tuesday, May 5th. Zacks Research upgraded shares of Repligen from a "hold" rating to a "strong-buy" rating in a research note on Thursday, July 30th. Finally, Weiss Ratings raised shares of Repligen from a "sell (d+)" rating to a "hold (c-)" rating in a report on Thursday, August 13th. Three analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, Repligen currently has a consensus rating of "Buy" and a consensus target price of $166.43.

Repligen Trading Down 7.1%

The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.64 and a current ratio of 9.05. The stock has a market cap of $9.49 billion, a P/E ratio of 230.34, a P/E/G ratio of 3.22 and a beta of 1.03. The stock has a 50-day moving average price of $153.08 and a 200-day moving average price of $133.28.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings data on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.45 by $0.09. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The company had revenue of $204.13 million for the quarter, compared to analysts' expectations of $201.59 million. During the same period in the prior year, the business earned $0.26 earnings per share. Repligen's revenue for the quarter was up 11.9% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. On average, equities research analysts expect that Repligen Corporation will post 2.06 EPS for the current year.

Insider Buying and Selling at Repligen

In other news, CFO Jason K. Garland sold 733 shares of the firm's stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $145.00, for a total transaction of $106,285.00. Following the sale, the chief financial officer owned 19,359 shares in the company, valued at approximately $2,807,055. This trade represents a 3.65% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 0.60% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in RGEN. California State Teachers Retirement System lifted its stake in Repligen by 13,158.5% during the second quarter. California State Teachers Retirement System now owns 8,201,681 shares of the biotechnology company's stock worth $1,119,037,000 after purchasing an additional 8,139,821 shares during the last quarter. United Capital Financial Advisors LLC bought a new stake in Repligen in the 2nd quarter worth approximately $380,756,000. Opti Capital Management LP bought a new stake in Repligen in the 4th quarter worth approximately $2,399,209,000. Maverick Capital Ltd. purchased a new stake in Repligen in the first quarter worth approximately $178,946,000. Finally, Wasatch Advisors LP bought a new position in Repligen during the first quarter valued at approximately $146,513,000. Institutional investors own 97.64% of the company's stock.

About Repligen

Repligen Corporation NASDAQ: RGEN is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen's offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company's core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source